A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

Eligibility Criteria

• * Participants who are characterized as having Lennox-Gastaut Syndrome (LGS) must fulfill all of the following criteria:
• * Onset of seizures at ≤8 years old
• * History of tonic/tonic-atonic seizures plus at least 1 of the following seizure type(s): atypical absence, atonic, myoclonic, focal impaired awareness, generalized tonic-clonic, nonconvulsive status epilepticus, or epileptic spasms
• * Presence of developmental plateauing or regression
• * History of electroencephalogram (EEG) showing generalized slow (\<2.5 Hertz \[Hz\]) spike-and-wave complexes
• * Participants who are characterized as having DEE (Other) must fulfill all of the following criteria:
• * Does not meet criteria for LGS
• * Onset of seizures at ≤5 years old
• * Presence of developmental plateauing or regression
• * History of multiple seizure types
• * History of interictal EEG background showing diffuse or multifocal slowing (with or without epileptiform activity)
• * The participant has a current occurrence of at least 1 of the following countable motor seizure types: generalized tonic-clonic, tonic (bilateral), clonic (bilateral), atonic (bilateral) with truncal/leg involvement, focal motor (including hemiclonic), and focal to bilateral tonic-clonic.
• * The participant has demonstrated an average of at least 4 countable motor seizures per month for each of the 3 months prior to Screening.
• * The participant has been taking 1 to 4 antiseizure medications (ASMs) at a stable dose for at least 4 weeks prior to Screening.
• * The participant, parent, or caregiver is willing and able (in the judgment of the investigator) to comply with completion of the diaries throughout the study.
• * The participant must be willing and able to provide written informed consent; in instances where the participant is unable to provide consent, an appropriate legal representative.
• * The participant has a diagnosis of Dravet Syndrome (DS) or has a mutation of the Sodium channel protein type 1 subunit alpha (SCN1A) gene consistent with DS.
• * The participant has been admitted to a medical facility for treatment of status epilepticus requiring mechanical ventilation within 3 months prior to Screening.
• * The participant has a neurodegenerative disorder as indicated by magnetic resonance imaging or genetic testing.
• * The participant has an acquired lesion/injury unrelated to the primary etiology that could contribute as a secondary cause of seizures.
• * The participant is receiving exclusionary medications.
• * The participant has used of any cannabis product or cannabidiol that is not in oral solution/capsule/tablet form, not obtained from a government-approved dispensary, or contains ≥50% Delta-9-tetrahydrocannabinol (THC).
• * The participant has unstable, clinically significant neurologic (other than the disease being studied; eg, recurrent strokes), psychiatric, cardiovascular (eg, pulmonary arterial hypertension, cardiac valvulopathy, orthostatic hypotension/tachycardia), pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, hematopoietic, or endocrine disease or other abnormality which may impact the ability of the participant to participate or potentially confound the study results.
• * The participant is unable or unwilling to comply with any of the study requirements or timelines.